Harlan & Ipsen Enter Agreement to Enhance Early Stage Development Services
Harlan Laboratories Contract Research Services (CRS) and Ipsen, a global specialty-driven pharmaceutical company, recently announced they have strengthened their collaboration with a new business agreement.
Under the terms of the agreement, the two companies have entered into a 3-year program on the development of early preclinical stage drug candidates with exclusivity in some specific areas. As a result, Harlan Laboratories has consolidated its standing in the early stage of the drug development process and has established itself as a leader in preclinical drug development.
Harlan Laboratories CRS is one of the world’s leading contract research organizations for the pharmaceutical, agrochemical, and chemical industries. The company offers a wide range of pharma services with particular expertise in inhalation, infusion, reproductive toxicology, neurotoxicology, immunology, genetic toxicology, oncology, and CNS.
The company’s specialized Pharma ADME (Absorption, Distribution, Metabolism and Excretion) department is primarily based at its site in
“This new agreement with Ipsen is in line with our strategy to satisfy the needs of the pharmaceutical industry in the preclinical arena and underlines our willingness to be close to our customers, helping them to make their drug candidates successful,” said Dr. Ciriaco Maraschiello, Head of Global General Toxicology, Harlan Laboratories CRS. “We are delighted to be working with Ipsen and believe this collaboration will offer clients an unrivalled level of expertise and support in the early development of new drug formulations. This is a very important agreement. which highlights our commitment to the pharma sector and reinforces our presence in the drug discovery segment of the drug development process.”
Total Page Views: 876
